Search Results
Your search for The matches 34600 pages
Showing 19901 - 19950Comparison of First-Line Treatments for EGFR-Mutant NSCLC
The phase III ARCHER 1050 trial has shown superior progression-free survival with the second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib vs gefitinib (Iressa) in the first-line treatment of advanced EGFR-mutant non–small cell lung...
Lymphoma Physician-Scientist Oliver Press, MD, PhD, Dies at 65
Oliver Press, MD, PhD, a blood cancer physician-scientist who made foundational contributions to the development of targeted cancer therapies, died Friday of complications from glioma. He was 65 years old. Dr. Press was the David and Patricia Giuliani/Oliver Press Endowed Chair for Cancer Research ...
FDA Conducts Global Operation to Protect Consumers From Potentially Dangerous Prescription Drugs Sold Online
The U.S. Food and Drug Administration (FDA), in partnership with international regulatory and law enforcement agencies, recently took action against more than 500 websites that illegally sell potentially dangerous, unapproved versions of prescription medicines, including opioids, antibiotics, and...
FDA Grants Priority Review for Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
On September 29, Roche announced the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application and granted Priority Review for pertuzumab (Perjeta), in combination with trastuzumab (Herceptin) and chemotherapy, for adjuvant treatment of...
Consolidative Radiotherapy for Limited Metastatic NSCLC
In a single-institution phase II trial reported in JAMA Oncology, Iyengar et al found that consolidative stereotactic ablative radiotherapy improved progression-free survival vs maintenance therapy alone in patients with limited metastatic non–small cell lung cancer (NSCLC). Study Details...
10-Year Survival With vs Without Axillary Dissection in Invasive Breast Cancer With Sentinel-Node Metastasis
As reported in JAMA by Giuliano et al, 10-year overall survival in the ACOSOG Z0011 (Alliance) trial with sentinel lymph node dissection (SLND) alone was noninferior to that with axillary lymph node dissection (ALND) in women with clinical T1 or T2 invasive breast cancer, no palpable axillary...
What Is the Most Important Factor Women Consider in Deciding on SERM Use to Reduce Their Risk of Breast Cancer?
Currently, two medications have been approved by the U.S. Food and Drug Administration to reduce the risk of breast cancer: tamoxifen and raloxifene. Both medications, selective estrogen receptor modulators (SERMs), have been shown to reduce the risk for breast cancer by up to 50% in prevention...
Biden Cancer Initiative: Accelerating Progress in Cancer Research
Earlier this year, at the Alexandria Center for Life Science, former Vice President Joe Biden and Jill Biden, PhD, launched the Biden Cancer Initiative, their new venture to continue the fight to make progress in cancer prevention, detection, treatment, and care. The Biden Cancer Initiative will...
Addition of Cetuximab to Concurrent Chemoradiation in Esophageal Cancer
The phase III NRG Oncology RTOG 0436 trial has shown no survival benefit of adding cetuximab (Erbitux) to paclitaxel/cisplatin and radiation therapy in patients with esophageal cancer treated without surgery. These results were reported by Mohan Suntharalingam, MD, MBA, of the Marlene and Stewart...
ASTRO 2017: Shorter Course of Radiation Treatment Safe for Breast Cancer Patients Under 50
A higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of breast cancer patients under age 50 than it is in older patients. This is the finding of a study led by researchers from Perlmutter Cancer Center at New York University (NYU)...
Molecular Profiling of Key Survival Proteins in B-Cell Lymphoma Subtypes
Investigators at the Sidney Kimmel Cancer Center at Jefferson uncovered potential new proteins that contribute to the development and progression of several types of lymphoma. Their findings were published by Adams et al in Clinical Cancer Research. The researchers focused their attention on...
Nivolumab Approved in Japan for Unresectable Advanced or Recurrent Gastric Cancer That Has Progressed After Chemotherapy
On September 22, Bristol-Myers Squibb Company announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) approved nivolumab (Opdivo) for the treatment of unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. This approval was based on the phase III ...
Pooled Analysis Safety Profile of Combination Immunotherapy for Advanced Melanoma
In a retrospective study reported in the Journal of Clinical Oncology, Sznol et al have provided a pooled safety profile of combination nivolumab (Opdivo) and ipilimumab (Yervoy) treatment in patients with advanced melanoma. Study Details The study included data from 448 patients from a phase Ib...
Addition of MET Inhibitor to First-Line Chemotherapy in Advanced Gastric Cancer
The phase III RILOMET-1 trial showed no survival benefit of adding the MET inhibitor rilotumumab to first-line epirubicin, cisplatin, and capecitabine in patients with advanced MET-positive gastric or gastroesophageal junction adenocarcinoma. These results were reported in The Lancet Oncology by...
Association Between Vasectomy and Prostate Cancer
A systematic review and meta-analysis has found no association between vasectomy and high-grade, advanced, or fatal prostate cancer but a weak association with any prostate cancer. These findings were reported in JAMA Oncology by Bimal Bhindi et al. R. Jeffrey Karnes, MD, of the Mayo Clinic,...
Adjuvant Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma
The phase III Checkmate 238 trial has shown improved recurrence-free survival with adjuvant nivolumab (Opdivo) vs ipilimumab (Yervoy) in patients with resected advanced melanoma. The findings were reported by Jeffrey Weber and colleagues in The New England Journal of Medicine. Study Details In the ...
Performance Measures for Cervical Cancer Screening
Health-care systems use performance measures for cervical cancer screening based on guidelines from such organizations as the American College of Obstetricians and Gynecologists to monitor the appropriateness of cervical cancer screening. According to the performance measure in the Healthcare...
Adding Sorafenib to Transarterial Chemoembolization in Hepatocellular Carcinoma
As reported in The Lancet Gastroenterology & Hepatology by Tim Meyer, MBBS, of the University College London, and colleagues, the UK phase III TACE 2 trial has shown no progression-free survival benefit with the addition of sorafenib (Nexavar) to transarterial chemoembolization in patients...
Shorter Course of Radiation Therapy Safe for Younger Women With Breast Cancer
A higher-dose, shorter form of radiation is safe, effective, and no more damaging to the breast tissue or skin of women with breast cancer under age 50 than it is in older patients, according to findings led by researchers from Perlmutter Cancer Center at NYU Langone Health, and presented at the...
Cancer Has Plagued My Family
My father, who was a physician, taught me at an early age to pay attention to any changes in my body. His advice has stood me in good stead for more than 83 years and probably saved my life more than once. In 1984, just before I turned 50, something was bothering me about my right breast. I could...
Study Finds Liquid Biopsy May Provide Predictive Biomarkers for Checkpoint Inhibitor Response
Although checkpoint inhibitor–based immunotherapy has revolutionized treatment for a variety of cancers, the majority of patients with cancer do not respond to the therapy, and a subset of patients may even experience hyperprogression. Many patients also experience some degree of...
Epithelioma Tubule De Nez, Albumen Print Paris, 1872
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photo below is from the volume titled “The Anesthesia Era: 1845–1875.” The photograph...
FDA Grants Accelerated Approval to Pembrolizumab for Advanced Gastric Cancer
On September 22, 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda) for patients with recurrent locally advanced or metastatic, gastric or gastroesophageal junction adenocarcinoma whose tumors express programmed cell death ligand 1 (PD-L1) as ...
Avelumab in Locally Advanced or Metastatic Urothelial Carcinoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 9, 2017, avelumab (Bavencio) was granted...
Durvalumab in Advanced Urothelial Carcinoma Progressing After Platinum Therapy
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 1, 2017, durvalumab (Imfinzi) was granted...
Current Oncology Landscape
ASCO released a landmark strategic plan to guide future efforts for increasing racial and ethnic diversity in the oncology workforce. The ultimate goal is to develop a workforce that provides high-quality cancer care to racial and ethnic populations who experience persistent disparities in access...
Increasing Racial and Ethnic Diversity in the Oncology Workforce
Although significant progress has been made in cancer incidence and mortality in the United States over the past 2 decades—the death rate fell 23% between 1991 and 20121—not everyone is benefiting equally. According to the American Cancer Society, blacks have the highest death rate and shortest...
National Committee for Quality Assurance Recognizes Sidney Kimmel Cancer Center at Jefferson
The Sidney Kimmel Cancer Center of the Thomas Jefferson University in Philadelphia has announced the receipt of two accolades by the National Committee for Quality Assurance (NCQA). Jefferson Oncology Medical Associates has been recognized by the NCQA for patient-centered specialty practice (PCSP)...
Combination of Rituximab and Hyaluronidase Human for Subcutaneous Use in Lymphoma and Leukemia
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 22, 2017, the combination of rituximab (Rituxan)...
Endocrine Society Names V. Craig Jordan, OBE, PhD, 2018 Laureate
V. Craig Jordan, OBE, PhD, has been recognized by the Endocrine Society as the 2018 Laureate of the Gerald D. Aurbach Award for Outstanding Translational Research. Dr. Jordan is the Dallas/Fort Worth Living Legend Chair of Cancer Research in the Department of Breast Medical Oncology at The...
Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated
The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up ...
With Financial Toxicity in Oncology Care on the Rise, Providers Need to Help Address Patients’ Financial Issues
At the 2017 ASCO Quality Care Symposium, Dan Sherman, MA, LPC, discussed potential solutions to the persistent challenge of financial toxicity in the oncology setting. Mr. Sherman is a clinical financial consultant and Founder and President of The Navectis Group, Caledonia, Michigan. Rather than...
Anthony Back, MD, to Receive Inaugural Walther Cancer Foundation Award
ASCO will honor Anthony Back, MD, with its inaugural Walther Cancer Foundation Palliative and Supportive Care in Oncology Endowed Award and Lecture. Endowed by the Walther Cancer Foundation,* this award and lecture was established to recognize a distinguished lecturer and leader with multiple,...
Recognizing the Importance of a Work-Life Balance in Oncology
The ASCO Post introduces this new department, Living a Full Life, in which we will share insightful narratives of oncology professionals highlighting personal aspects of these clinicians’ lives separate from the world of oncology. We also intend to open a dialogue about the challenges that today’s...
Cancer Policy Priorities Front and Center on Capitol Hill
On September 27 and 28, more than 100 ASCO volunteers headed to Capitol Hill to participate in the 2nd Annual ASCO Advocacy Summit. During the Summit, advocates met with members of Congress and staff to educate them on critical issues affecting patients and providers and to encourage policymakers...
Obtaining a Second Graduate Degree During Fellowship: Things to Consider
KAH POH (MELISSA) LOH, MBBCh BAO Institution: Fellow, University of Rochester Medical CenterMember since: 2013ASCO activities: Trainee Council Hematology and oncology fellowship training requires at least 3 years to complete. For fellows who wish to single board in either hematology or oncology, a ...
ASCO and Friends of Cancer Research Release Comprehensive Recommendations to Broaden Eligibility Criteria for Cancer Clinical Trials
ASCO and Friends of Cancer Research (Friends) are calling for the use of more inclusive eligibility criteria for cancer clinical trials in a new Special Series in the Journal of Clinical Oncology (JCO). The series provides a comprehensive examination of eligibility criteria for cancer clinical...
ASCO Concerned With MIPS Part B Reimbursement Assessments in QPP Proposal
ASCO submitted comments to the Centers for Medicare & Medicaid Services (CMS) on its proposed rule outlining changes to the Quality Payment Program (QPP) for 2018. In a letter to CMS Administrator Seema Verma, ASCO President Bruce E. Johnson, MD, FASCO, made recommendations regarding the two...
ASCO’s QOPI Certification Program™ Recognizes Three Oncology Practices in Spain
ASCO has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program™, LLC (QCP). The accreditations were given on September 8, at the European Society for Medical Oncology (ESMO) 2017 Congress in...
Educate and Support Your Patients With ASCO Answers Materials
Provide your patients with ASCO-approved information on cancer. ASCO Answers materials are available as fact sheets and booklets, covering many types of cancer as well as treatments and side effects. Order printed copies online today through the ASCO Bookstore at www.cancer.net/estore. Enjoy free ...
Spotlight on Women Who Conquer Cancer
Women Who Conquer Cancer is a group dedicated to advancing cancer research by supporting young female researchers early in their careers through Conquer Cancer Foundation (CCF) Young Investigator Awards (YIAs). These 1-year grants give promising researchers the boost they need to get started on...
CCF Researcher Spotlight: Rizwan Romee, MD
RIZWAN ROMEE, MD Assistant Professor of Medicine & Clinical Director, Haploidentical Transplant Program Washington University in St. Louis St. Louis, Missouri Acute myeloid leukemia, or AML, is the most common type of acute blood cancer in the adult population and can be very difficult to...
Clinical Trials Actively Recruiting Patients With Breast Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies focused on patients with breast cancer. These studies highlight neoadjuvant combination therapy, cell vaccines, novel imaging techniques, radiotherapy, and more. All of the studies are...
FDA Expands Approval of Ipilimumab to Pediatric Patients 12 Years and Older
On July 24, the U.S. Food and Drug Administration (FDA) expanded the indication for ipilimumab (Yervoy) injection for intravenous use now to include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Ipilimumab was evaluated in 2 trials of...
ASTRO 2017: Uninsured Patients With Cancer Saw Increased Coverage for Care Following Medicaid Expansion
A new study found that Medicaid expansion enacted as part of the Patient Protection and Affordable Care Act (ACA) improved coverage for care for patients with cancer receiving radiation therapy and potentially decreased health-care disparities. Analysis of more than 197,000 patient records from one ...
ASTRO 2017: Accelerated Breast Radiation Therapy Following Mastectomy Can Shorten Treatment Time While Maintaining Tumor Control
Radiation therapy following mastectomy for intermediate-stage, high-risk breast cancer can be shortened from 5 to 3 weeks while maintaining tumor control rates in the breast and surrounding region that are equivalent to conventional treatment, according to research presented by Sun et al at the...
Preexisting Mental Illness and All-Cause and Breast Cancer Mortality in Elderly Breast Cancer Patients
A study using linked Surveillance, Epidemiology, and End Results–Medicare data has shown a significantly increased risk of all-cause mortality and a nonsignificantly increased risk of breast cancer–specific mortality in elderly breast cancer patients with preexisting severe mental...
Changes in Insurance Coverage and Diagnosis Stage After Affordable Care Act Implementation
Jemal et al found decreases in the percentage of uninsured patients and trends toward earlier diagnosis among nonelderly patients with cancer after implementation of the Affordable Care Act (ACA). Their findings were reported in the Journal of Clinical Oncology. Study Details The study used...
Combination Therapy for Previously Untreated BRAF V600E–Mutant Metastatic NSCLC
In a phase II trial, the combination of dabrafenib (Tafinlar) plus trametinib (Mekinist) produced durable responses in a cohort of patients with previously untreated BRAF V600E–mutant metastatic non–small cell lung cancer (NSCLC). The findings were reported in The Lancet Oncology by...
